SSA
RVNC

Schonfeld Strategic Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Schonfeld Strategic Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,400
Closed -$40.7K – 2590
2024
Q4 		$40.7K Sell
13,400
-48,900
-78% -$213K ﹤0.01% 1881
2024
Q3 		$323K Sell
62,300
-131,291
-68% -$652K ﹤0.01% 1624
2024
Q2 		$498K Buy
+193,591
New +$661K ﹤0.01% 1494
2024
Q1 		– Sell
-266,039
Closed -$2.34M – 2484
2023
Q4 		$2.34M Buy
266,039
+64,405
+32% +$528K 0.02% 748
2023
Q3 		$2.31M Buy
201,634
+117,634
+140% +$2.26M 0.02% 784
2023
Q2 		$2.13M Buy
84,000
+28,999
+53% +$903K 0.02% 732
2023
Q1 		$1.77M Sell
55,001
-116,350
-68% -$3.63M 0.02% 727
2022
Q4 		$3.16M Sell
171,351
-45,548
-21% -$1.04M 0.03% 648
2022
Q3 		$5.86M Buy
+216,899
New +$4.4M 0.05% 481
2021
Q3 		– Sell
-9,900
Closed -$293K – 2539
2021
Q2 		$293K Buy
+9,900
New +$286K ﹤0.01% 1491
2018
Q2 		– Sell
-83,700
Closed -$2.58M – 1013
2018
Q1 		$2.58M Sell
83,700
-11,657
-12% -$375K 0.19% 153
2017
Q4 		$3.41M Buy
+95,357
New +$2.74M 0.28% 102

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Schonfeld Strategic Advisors's RVNC Position: Q1 2025 in Review

Schonfeld Strategic Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 13,400 shares — an estimated $40.7K sold.

Schonfeld Strategic Advisors first reported a position in RVNC in Q4 2017 and held it in 12 quarters. The position peaked at $5.86M in Q3 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Schonfeld Strategic Advisors reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 13,400 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $40.7K.
  • Schonfeld Strategic Advisors first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 12 quarters.
  • Schonfeld Strategic Advisors's Revance Therapeutics, Inc. position peaked at $5.86M in Q3 2022.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2025, filed 15 May 2025.